Gastric Cancer (GC) Clinical Trials

11 recruiting

Gastric Cancer (GC) Trials at a Glance

11 actively recruiting trials for gastric cancer (gc) are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in Shanghai, Cerritos, and Chongqing. Lead sponsors running gastric cancer (gc) studies include City of Hope Medical Center, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, and Beijing Friendship Hospital.

Browse gastric cancer (gc) trials by phase

Treatments under study

About Gastric Cancer (GC) Clinical Trials

Looking for clinical trials for Gastric Cancer (GC)? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Gastric Cancer (GC) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Gastric Cancer (GC) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 3

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.

Esophageal CancerGastric Cancer (GC)Gastroesophageal Junction
SOFIE200 enrolled10 locationsNCT07217704
Recruiting

Immediate and Functional Results of Different Types of Reconstructions After Proximal Gastrectomy For Gastric and Esophagogastric Junction Cancer

Gastric Cancer (GC)Siewert Type III Adenocarcinoma of Esophagogastric JunctionSiewert Type II Adenocarcinoma of Esophagogastric Junction
P. Herzen Moscow Oncology Research Institute400 enrolled1 locationNCT07441785
Recruiting
Phase 1

A Study of SH009 Injection in Patients With Advanced Solid Tumors.

Esophageal CancerBreast Cancer (Locally Advanced or Metastatic)Lung Cancer (NSCLC)+4 more
Nanjing Sanhome Pharmaceutical, Co., Ltd.150 enrolled1 locationNCT07390838
Recruiting
Phase 3

Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer

Gastric Cancer (GC)Adjuvant ChemotherapyOxaliplatin+2 more
Ruijin Hospital387 enrolled5 locationsNCT07366528
Recruiting

Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer

Gastric Cancer (GC)HIPECPeritoneal Metastases From Gastric Cancer+1 more
Ukrainian Society of Clinical Oncology200 enrolled1 locationNCT07313579
Recruiting
Phase 2

Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

Gastric Cancer (GC)
Beijing Friendship Hospital32 enrolled1 locationNCT07315854
Recruiting
Phase 2

SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure

Gastroesophageal Junction AdenocarcinomaGastric Cancer (GC)
Jingdong Zhang40 enrolled1 locationNCT07311408
Recruiting

A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer

Pancreatic Ductal Adenocarcinoma (PDAC)CholangiocarcinomaHepatocellular Carcinoma (HCC)+3 more
City of Hope Medical Center1,000 enrolled1 locationNCT07224750
Recruiting
Not Applicable

PPG vs. ICG in Gastrointestinal Resections

Gastric Cancer (GC)Postoperative ComplicationsGastrointestinal Neoplasms+2 more
Saint Petersburg State University, Russia200 enrolled3 locationsNCT06222645
Recruiting

The Possible Range of No.4sb Lymph Node Dissection of Locally Advanced Distal Gastric Cancer

Gastric Cancer (GC)No.4sb
Tianjin Medical University Cancer Institute and Hospital400 enrolled1 locationNCT07183150
Recruiting
Phase 2

Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)

Neoadjuvant TherapyRadiotherapyImmunotherapy+2 more
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University40 enrolled1 locationNCT07165847